Here are the 10-K annual reports from Kairos Pharma, Ltd. (KAPA) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow KAPA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full KAPA filings page.
Kairos Pharma, Ltd. is a clinical-stage biopharmaceutical company developing seven oncology candidates aimed at overcoming drug resistance and immune suppression in cancers such as prostate, lung, breast cancer and glioblastoma. Its portfolio includes five Kairos-developed immunotherapies (KROS 101, 102, 201, 301 and 401) and two Enviro-originated biologics (ENV 105 and ENV 205).
ENV 105 is in a randomized Phase 2 prostate cancer trial with apalutamide and a Phase 1 trial in EGFR-mutant non-small cell lung cancer, while KROS 201 targets glioblastoma through activated T cells. ENV 205 is being advanced for chemotherapy resistance and cachexia. The company relies on extensive IP licensed from Cedars-Sinai and Tracon.
Kairos highlights recent capital raises, including a 2024 IPO, a 2025 PIPE with pre-funded and common warrants, a $30 million equity line, and a 2026 at-the-market program, but also discloses ongoing losses, substantial funding needs, and significant development, regulatory and financing risks.